BRAF and colorectal carcinoma: The mice were subsequently treated with vehicle alone, VPA, or suboptimal doses of OXA plus capecitabine (CHT), with or without an anti-VEGF antibody, an established drug for the treatment of CRC patients with RAS or BRAF mutations, or with VPA plus CHT with or without anti-VEGF, as illustrated schematically in Fig. 5a and Supplementary Fig. 9a.